retatrutide trial of next-gen weight-loss drug brings it one step closer to FDA approval Retatrutide UK: 2026 Clinical Trial

References Jastreboff AM, Kaplan LM, Fras JP, et al

In Phase 3 TRIUMPH-1 data, dysesthesia occurred in 5.1%, 12.3%, and 12.5% of participants taking retatrutide 4 mg, 9 mg, and 12 mg, compared with 0.9% of participants receiving placebo

Semaglutide for managing overweight and obesity Recommendations chapter (TA875)

Do not inject a double dose to make up for a missed one

Units, milligrams, milliliters, IU markings, they all blur together when you are staring at a tiny syringe trying to figure out how far to pull the plunger

Healthy habits can start at work with something as simple as encouraging more movement in the office or promoting healthy eating